Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8191 to 8205 of 8993 results

  1. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

  2. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

  3. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

  4. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

  5. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

  6. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

  7. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

  8. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

  9. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

  10. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued Reference number: GID-TA10193

  11. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

  12. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued Reference number: GID-TA10179

  13. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued Reference number: GID-TA10687

  14. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued Reference number: GID-TA11175

  15. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued Reference number: GID-TA10264